Skip to main content
EJNMMI Radiopharmacy and Chemistry
Fig. 4 | EJNMMI Radiopharmacy and Chemistry

Fig. 4

From: Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [111In]In-BnDTPA-trastuzumab-NLS injection: a theranostic agent for imaging and Meitner-Auger Electron (MAE) radioimmunotherapy of HER2-positive breast cancer

Fig. 4

Representative direct (saturation) receptor-binding curve for the binding of 111In[In]-BnDTPA-trastuzumab-NLS prepared from kit Lot 18N008 to HER2-positive SK-BR-3 human breast cancer (BC) cells. Shown are the total binding (TB) and non-specific binding (NSB) in the presence of an excess (15.2 μmoles/L) of trastuzumab. The specific binding (SB) was calculated by subtracting NSB from TB. In this representative HER2 binding assay, the Ka was 3.8 ± 0.6 × 108 L/mole and the Bmax was 1.0 ± 0.03 × 106 sites per cell

Back to article page